Scientists at the University of Cincinnati are pioneering efforts to disrupt the lifecycle of the parasite responsible for Chagas disease, an often-overlooked infection that affects millions across the Americas. Published in mBio, their study explores genetic vulnerabilities in the parasite, offering hope for future treatments to combat this deadly illness.
Chagas disease, transmitted by kissing bugs, infects an estimated 6–8 million people, including 300,000 in the U.S. Many remain unaware of their infection until severe symptoms emerge decades later. The parasite, Trypanosoma cruzi, undergoes four lifecycle stages to survive transitions between insects and humans, evading immune defenses and medications by hiding within host cells.
Using gene-editing tools, researchers identified key proteins that enable the parasite to adapt to environmental changes. “The goal is to find its weaknesses to fight the disease,” said lead researcher Noelia Lander, who praised the parasite’s survival mechanisms while emphasizing the urgency of disrupting its lifecycle. Graduate student Milad Ahmed noted that chronic infections render existing treatments ineffective, underscoring the need for new approaches.
“The parasite can’t survive if it can’t transform during its lifecycle,” Lander explained. Co-author Miguel Chiurillo added that understanding these adaptive proteins is critical for developing targeted therapies.
The study highlights the potential of lifecycle interruption as a strategy to cure Chagas disease. Future research will focus on translating these findings into treatments to prevent the parasite’s survival and reduce the global burden of this silent killer.
Add comment